TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Father salivary oxytocin (OT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Infant salivary oxytocin (OT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Engagement behavior (social gaze, exploration, social reciprocity)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: relief of epigastric pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: relief of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: survival without supplemental oxygen or on ventilator
Endpoint domain: Mortality/survival
Primary endpoint: oxygenation index response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of alpha-hydroxymidazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of alpha-hydroxymidazolam metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diplopia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Hand hygiene (HH) dispensing episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol-based handrub consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MTS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in joint angles R1 and R2 in MTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross motor score in GMFM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children receiving at least the first dose of IPTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: voluntary withdrawals from treatment
Endpoint domain: Adverse events/effects
Primary endpoint: underwater survival time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in proinflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hospitalization or mortality
Endpoint domain: Mortality/survival
Primary endpoint: RV peak systolic global longitudinal strain (GLε)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: arterial calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mean LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urine osmolality rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Induced CD8+ T-cell responses to HIV peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Induced CD4+ T-cell responses to tetanus toxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local pain frequency after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Corneal esthesiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical site infection (SSI) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Wound-related treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MADRS response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MADRS remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent clearance of rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent clearance of 25-deacetyl-rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EVG Ctau concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FTC exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tenofovir exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microTBS value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pain (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-statistic of combined biomarker model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean minimal coronary artery diameter decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: duration of pain episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular end diastolic volume (LVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in frequency of CPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Support for coercion vs autonomy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to resolution of diarrhea (TTROD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDI recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure decrease
Endpoint domain: Adverse events/effects
Primary endpoint: Bioequivalence based on pharmacokinetic measurements (AUC and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full-scale IQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Paracetamol use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity for detecting metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity for detecting metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the curve (Az)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Signs of spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Recovery of arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Improvement (TI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage controlled at the end of study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vasoconstriction threshold reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shivering threshold reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF% progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression to persistent AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from AF/atrial tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate of medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of facial hyperpigmented spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CV mortality and morbidity
Endpoint domain: Mortality/survival
Primary endpoint: ACS Response Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulance use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Confidence in recognizing and responding to symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain at rest and in motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tape position and descent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nonvascular deaths related to infection
Endpoint domain: Mortality/survival
Primary endpoint: Deaths from bleeding complications
Endpoint domain: Mortality/survival
Primary endpoint: ISWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ESWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRDQ total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functionality improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global QoR-40 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative mean tramadol dose after 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: simple Crohn's disease activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracic angle decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar angle decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk-flexion strength increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expiratory volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in pain intensity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite pain index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation of evidence-based processes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of total emergency visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Diastolic blood pressure (BPd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean blood pressure (BPm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perfusion pressure (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Periodontal Inflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCF IL-1β levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GCF TNF-α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: burst pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general Bright Futures confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: oral health confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clinical performance skills in oral health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hand OSCE scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean knee OSCE scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: TAT-III levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prothrombin fragments F1 + 2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: general medicine knowledge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory and cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scale assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in skin prick test sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in cat-specific IgG4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in CD4+/IL-4+ PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Avoidance of hysterectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of symptoms of menorrhagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of elevated HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of ketamine and midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonverbal posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of chemotherapy data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of chemotherapy data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean doses of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: satisfaction with health promotion programs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incremental area under the curve (AUC) for capillary glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of apically extruded debris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ambulatory 24-h blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: primary efficacy measure scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erythema levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exudation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hot flushes experienced per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of night sweats experienced per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of OPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: culture success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcome comparable to recombinant FSH‐alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total KMI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KMI scores for fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women with a regular exercise habit
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in decayed, missing, and filled teeth (DMFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in decayed, missing, and filled surfaces (DMFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fracture prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the curve for hydrogen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Social phobia measure (SPAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients discussed at a MDT meeting
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of players with hamstring isokinetic testing deficit of more than 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum creatinine level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Gallbladders free of stones after six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burning oral pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sense of taste disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal fit of prostheses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Y-BOCS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression-Severity of Illness scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full responders rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6-month major adverse cardiovascular events rate
Endpoint domain: Mortality/survival
Primary endpoint: 1-year event-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: reduction in irritability symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotionalism
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Arterial pressure of carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative hypercapnia
Endpoint domain: Adverse events/effects
Primary endpoint: Glasgow Coma Scale level at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of relative reduction of the wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time for urethro‐ileal anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: postoperative continence rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Discordant risk perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hyperintense T2 signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amplitude of MEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: peak torque of plantarflexor and dorsiflexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 10 m walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of 25(OH)D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perception of effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weighted mean serum cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Drop in HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate peak sputum tobramycin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intragastric acid production reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Heartburn improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of contrast agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: meal-induced gastric accommodation reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peak CTNI levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gastric mucosal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oxygen transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who developed any skeletal event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of skeletal events per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of stratum 2 patients
Endpoint domain: Mortality/survival
Primary endpoint: Recolonization with S. aureus at 12 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: active minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum interartery systolic blood pressure differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants in intervention areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants in control areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Google AdWords targeting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative emetic protection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes